These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36155307)

  • 1. Relapse of first-episode schizophrenia patients and neurocognitive impairment: The role of dopaminergic and anticholinergic burden.
    Cuesta MJ; Ballesteros A; Sánchez-Torres AM; Amoretti S; López-Ilundain JM; Merchán-Naranjo J; González-Ortega I; Salgado P; Rodriguez-Jimenez R; Roldán-Bejarano A; Sarró S; Ibáñez Á; Usall J; Escartí MJ; Moreno-Izco L; Mezquida G; Parellada M; González-Pinto A; Berrocoso E; Bernardo M;
    Schizophr Res; 2022 Oct; 248():331-340. PubMed ID: 36155307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Anticholinergic Burden on Verbal Memory Performance in First-Episode Psychosis.
    Belkacem A; Lavigne KM; Makowski C; Chakravarty M; Joober R; Malla A; Shah J; Lepage M
    Can J Psychiatry; 2023 Dec; 68(12):894-903. PubMed ID: 37254533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory.
    Ballesteros A; Sánchez Torres AM; López-Ilundáin J; Mezquida G; Lobo A; González-Pinto A; Pina-Camacho L; Corripio I; Vieta E; de la Serna E; Mané A; Bioque M; Moreno-Izco L; Espliego A; Lorente-Omeñaca R; Amoretti S; Bernardo M; Cuesta MJ;
    Psychol Med; 2021 Sep; 51(12):2044-2053. PubMed ID: 32326991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia: a 3-year follow-up study.
    Sánchez-Torres AM; Amoretti S; Enguita-Germán M; Mezquida G; Moreno-Izco L; Panadero-Gómez R; Rementería L; Toll A; Rodriguez-Jimenez R; Roldán A; Pomarol-Clotet E; Ibáñez Á; Usall J; Contreras F; Vieta E; López-Ilundain JM; Merchán-Naranjo J; González-Pinto A; Berrocoso E; Bernardo M; Cuesta MJ;
    Eur Neuropsychopharmacol; 2023 Feb; 67():53-65. PubMed ID: 36495858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.
    Joshi YB; Thomas ML; Braff DL; Green MF; Gur RC; Gur RE; Nuechterlein KH; Stone WS; Greenwood TA; Lazzeroni LC; MacDonald LR; Molina JL; Nungaray JA; Radant AD; Silverman JM; Sprock J; Sugar CA; Tsuang DW; Tsuang MT; Turetsky BI; Swerdlow NR; Light GA
    Am J Psychiatry; 2021 Sep; 178(9):838-847. PubMed ID: 33985348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive burden of anticholinergic medications in psychotic disorders.
    Eum S; Hill SK; Rubin LH; Carnahan RM; Reilly JL; Ivleva EI; Keedy SK; Tamminga CA; Pearlson GD; Clementz BA; Gershon ES; Keshavan MS; Keefe RSE; Sweeney JA; Bishop JR
    Schizophr Res; 2017 Dec; 190():129-135. PubMed ID: 28390849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?
    Ballesteros A; Sánchez-Torres AM; López-Ilundain JM; Cabrera B; Lobo A; González-Pinto AM; Díaz-Caneja C; Corripio I; Vieta E; de la Serna E; Bobes J; Usall J; Contreras F; Lorente-Omeñaca R; Mezquida G; Bernardo M; Cuesta MJ;
    Psychol Med; 2018 Oct; 48(13):2247-2256. PubMed ID: 29331153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.
    Vinogradov S; Fisher M; Warm H; Holland C; Kirshner MA; Pollock BG
    Am J Psychiatry; 2009 Sep; 166(9):1055-62. PubMed ID: 19570929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticholinergic Burden and Cognition in Older Patients With Schizophrenia.
    Tsoutsoulas C; Mulsant BH; Kumar S; Ghazala Z; Voineskos AN; Menon M; Pollock BG; Rajji TK
    J Clin Psychiatry; 2017; 78(9):e1284-e1290. PubMed ID: 29188908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia.
    Haddad C; Salameh P; Sacre H; Clément JP; Calvet B
    BMC Psychiatry; 2023 Jan; 23(1):61. PubMed ID: 36694187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the effects of treatment resistance and anticholinergic burden on cognitive function domains in patients with schizophrenia.
    Chan SKW; Pang TSW; Tsui HKH; Suen YN; Yan WC; Tsui CF; Poon LT; Chan CWH; Lo A; Cheung KM; Hui CLM; Chang WC; Lee EHM; Chen EYH; Honer WG
    Psychiatry Res; 2024 Jul; 337():115985. PubMed ID: 38820652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.
    Ang MS; Abdul Rashid NA; Lam M; Rapisarda A; Kraus M; Keefe RSE; Lee J
    J Clin Psychopharmacol; 2017 Dec; 37(6):651-656. PubMed ID: 29016375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticholinergic Drug Burden and Neurocognitive Performance in the Study of Latinos-Investigation of Neurocognitive Aging.
    Posis AIB; Tarraf W; Gonzalez KA; Soria-Lopez JA; Léger GC; Stickel AM; Daviglus ML; Lamar M; Zeng D; González HM
    J Alzheimers Dis; 2022; 86(1):53-65. PubMed ID: 35001889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
    Minzenberg MJ; Poole JH; Benton C; Vinogradov S
    Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.
    Ogino S; Miyamoto S; Miyake N; Yamaguchi N
    Psychiatry Clin Neurosci; 2014 Jan; 68(1):37-49. PubMed ID: 24102938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between level of cognitive impairments and functional outcome trajectories in first-episode schizophrenia.
    Fu S; Czajkowski N; Rund BR; Torgalsbøen AK
    Schizophr Res; 2017 Dec; 190():144-149. PubMed ID: 28302394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling cognitive impairment in treatment-resistant schizophrenia patients.
    Frydecka D; Beszłej JA; Gościmski P; Kiejna A; Misiak B
    Psychiatry Res; 2016 Jan; 235():133-8. PubMed ID: 26706131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia.
    Mäkipelto V; Tuulio-Henriksson A; Hakulinen C; Niemelä S; Lähteenvuo M; Wegelius A; Kieseppä T; Isometsä E; Tiihonen J; Kampman O; Lahdensuo K; Mazumder A; Suvisaari J; Holm M
    Schizophr Res; 2024 Apr; 266():118-126. PubMed ID: 38401410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.